Press Release 22 September 2023 10:00:00 CEST



Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Levodopa/Benserazide tablets.

"This combination of medicines is used to treat Parkinson's disease. People with Parkinson's disease do not have enough dopamine in certain parts of their brains. This can result in slow movements, stiff muscles and tremor. With the addition of Levodopa /Benserazide we have also secured a new partnership which can be used to source additional new products" says Mr Lars Minor CEO, Newbury Pharmaceuticals.

Regulatory filling will take place in the near future, and we aim to launch this medicine in Sweden where the total annual value of the market is estimated to be 4 MEUR according to DLMI Nordic Pharma Insights.

Newbury currently has over thirty (30) products in its portfolio and the first launches took place in 2022 with additional launches planned in a steady stream over the coming years.

For more information, contact:

Lars Minor, CEO

lars.minor@newburypharma.com

Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release 22 September 2023 10:00:00 CEST



Attachments

Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide